L
Lucence
Biotech & Life Sciences · Palo Alto, United States · Founded 2016
Precision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection MoreLess
Lucence is a pioneering company in the field of precision cancer care, specializing in ultrasensitive and non-invasive liquid biopsy tests. These tests are designed to detect and profile cancer using a single blood draw, making early detection more accessible and affordable. Lucence serves a diverse range of clients, including physicians and patients, who require accurate and actionable insights to guide their medical care. Operating in the healthcare and biotechnology market, Lucence leverages its proprietary technologies to capture both sequence and cell information, providing comprehensive cancer profiling. The company's business model revolves around offering these advanced diagnostic tests, generating revenue through the sale of their liquid biopsy solutions. By focusing on early cancer detection, Lucence aims to transform cancer care and improve patient outcomes.
Keywords: liquid biopsy, cancer detection, precision care, non-invasive, blood test, biomarkers, early detection, healthcare, biotechnology, diagnostics.
Company overview
Lucence company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Palo Alto, United States
- Employees
- 105
- Open positions
- 10
- Dealroom signal
- 56.6
Valuation & funding
Lucence funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2019 | $20M | $80M | SGInnovate · Boon Hwee Koh · Heliconia Capital Management · IHH Healthcare | — |
| SEED✓Equity / VC | Jan 2019 | $9.2M | $37M | Heliconia Capital Management · Boon Hwee Koh · Lim Kaling | — |
| SPINOUT✓Other financing | Apr 2016 | $0 | — | A*STAR | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 103 |
| 2025 | 96 |
| 2024 | 79 |
| 2023 | 79 |
| 2022 | 99 |
| 2021 | 88 |
| 2020 | 71 |
Growth signals
Lucence website traffic
Latest recorded traffic for Lucence is 4.1K monthly website visits, down 14.6% over the last three months. Lucence's team grew 9.4% over the past year.
Hiring
Open positions at Lucence
Current openings linked to this company in Dealroom.
Comparisons
Lucence compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lucence's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Lucence's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Lucence has talent and traffic
team presence
In the news
Latest news about Lucence
Recent press, funding announcements, and product moves mentioning Lucence — open to read from the original sources.
Market sentiment
What the market is saying about Lucence
An AI-synthesized read of the highest-engagement posts about Lucence on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lucence’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.